Waxman’s Oversight Committee Looks Into Drug-Eluting Stents
This article was originally published in The Gray Sheet
Executive Summary
The House Committee on Oversight and Government Reform is requesting information on the off-label use and marketing of drug-eluting stents
You may also be interested in...
Capitol Hill Roundup: Many Med-Tech Issues Are In Play For 2008
Health care may not have been the most debated issue on Capitol Hill in 2007, but it was close, and issues impacting the medical technology sector were in abundance
Capitol Hill Roundup: Many Med-Tech Issues Are In Play For 2008
Health care may not have been the most debated issue on Capitol Hill in 2007, but it was close, and issues impacting the medical technology sector were in abundance
Waxman queries FDA on Medtronic recall
House Committee on Oversight and Government Reform Chair Henry Waxman, D-Calif., requests information on FDA's oversight of Medtronic's Sprint Fidelis defibrillator leads in an Oct. 22 letter to the agency. Medtronic recalled the leads Oct. 15 due to a propensity for fractures that has been linked to patient deaths (1"The Gray Sheet" Oct. 22, 2007, p. 3). Noting what is "apparently a serious shortcoming in the agency's approval process for these devices," Waxman asks FDA why Medtronic was not required to submit clinical data to support the leads' safety and efficacy, what information Medtronic had provided about the fracture problem and how FDA responded, and whether the agency had created new policies for the oversight of defibrillators. Sen. Chuck Grassley, R-Iowa, sent FDA a similar letter Oct. 16